作者: Lize Cuypers , Marijn Thijssen , Arash Shakibzadeh , Ward Deboutte , Jamal Sarvari
DOI: 10.1016/J.MEEGID.2019.103966
关键词:
摘要: Abstract A tremendous upscale of screening and treatment strategies is required to achieve elimination the hepatitis C virus (HCV) in Iran by 2030. Among treated patients, at least 5–10% expected experience failure. To efficiently retreat cases with prior exposure NS5A NS5B drugs, knowledge on natural prevalence NS3 resistance key. The region 32 samples from sixteen Iranian HCV among which 6 injecting drug users, was amplified subjected deep sequencing. Amplification sequencing were successful 29 samples. reads assembled consensus sequences showed that patients infected HCV1a (37.5%), 7 HCV1b (43.8%) 3 HCV3a (18.7%). Nucleotide identities shared for >97% between intra-host sequences. Two resistant viruses, one solely comprising low frequency variants. Inferred phylogenies clustered together HCV1b, while a potential recombination event detected. We firstly report use Iran, demonstrate inhibitors as salvage therapy case retreatment stress importance prioritize users treatment.